Company intelligence / Profile preview

Release Therapeutics

Geneva, Geneva Canton, Switzerlandrelease-tx.com ↗

Ownership: Private
Development stage: Other

Overview

The company has demonstrated preclinical proof-of-concept in animal models of metachromatic leukodystrophy, showing reversal of disease progression after three months of ARSA enzyme replacement delivered via their encapsulated cell device. They are advancing to non-human primate studies following successful seed funding.

Therapeutic areas: Neurology
Modalities: Cell therapy (encapsulated allogeneic cell therapy)Enzyme replacement therapyDevice (implantable macroencapsulation device)Protein (therapeutic protein delivery)
Industry: Biotech

Drug pipeline

3 assets

Myo-P4

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Innovation Unit for Gene and Cell Therapy at Paris Brain Institute ("GENOV")

Beyond the preview

Go deeper on Release Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Release Therapeutics.

Explore the full profile